Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

Group 1 - Accuray Incorporated will participate in the Jefferies Global Healthcare Conference 2025, with a scheduled fireside chat on June 4th, 2025, at 5:30pm EDT/2:30pm PDT [1] - A live webcast of the conference call will be available on the company's Investor Relations website, with a replay accessible for 90 days [1] Group 2 - Accuray is focused on advancing radiation therapy to improve patient outcomes, offering innovative solutions for complex cases and simplifying treatment for more common cases [2] - The company is dedicated to continuous innovation in radiation therapy for oncology and neuro-radiosurgery, collaborating with clinicians and administrators to enhance patient recovery [2] - Accuray is headquartered in Madison, Wisconsin, and has facilities worldwide [2]

AdaptHealth (AHCO) 2025 Conference May 21, 2025 08:00 AM ET Speaker0 Relations in the room. Thank you guys very much for joining us. Thanks for having us, Ben. Yeah. I just wanted to kinda recap some of the dynamics that are going on in the quarter. Diabetes revenue declined 8%, but it's largely as expected. We're doing a overhaul of that segment, but you noticed some better than expected sequential developments and setups. Maybe you can kinda walk us through what you're seeing and and kinda how we you're f ...

Core Viewpoint - Quipt Home Medical Corp. has received an unsolicited non-binding proposal from Forager Capital Management to acquire 100% of its common shares at a price of $3.10 per share [1] Group 1: Proposal Details - The proposal is non-binding, conditional, and indicative, indicating that it is not a formal offer yet [1] - The Company has a Non-Disclosure and Standstill Agreement with Forager, which prohibits Forager from acquiring any equity securities or assets of Quipt for six months without prior approval from the Board [2] - The Board has not provided any prior written approval for the proposal, adhering to the terms of the Agreement [2] Group 2: Company Strategy and Operations - Quipt focuses on providing in-home monitoring and disease management services, particularly in respiratory care, and aims to expand its offerings for chronic disease management [4] - The primary business objective is to create shareholder value by offering a broader range of services to patients, thereby increasing annual revenue per patient [4] - The Company is committed to driving sustainable value for its shareholders and will consult with financial and legal advisors regarding the proposal [3]

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the trad ...

Home Depot on Tuesday held its forecast for sales in 2025, while one executive reportedly said the retailer won't raise prices because of tariffs, as other companies flag concerns and cut projections, citing uncertainty over U.S. tariffs. Rivian lowered its targets for vehicle deliveries and capital spending for 2025, noting the "current global economic landscape presents significant uncertainty," including "evolving trade regulation, policies" and tariffs. AMD said the company expects to lose $1.5 billion ...

Core Insights - The U.S. Gynecological Chairs and Tables Market was valued at USD 194.8 Million in 2024 and is projected to reach USD 283.8 Million by 2030, with a CAGR of 6.50% [1][9]. Market Growth Drivers - The expansion of the U.S. gynecological chairs and tables industry is driven by the increasing adoption of minimally invasive surgical (MIS) techniques, which enhance procedural efficiency and patient comfort [2][4]. - The demand for laparoscopic procedures is significantly influenced by the prevalence of uterine fibroids, affecting approximately 26 million women in the U.S. aged 15 to 50 [3][4]. Market Segmentation - Gynecological chairs dominate the U.S. market share, while gynecological tables are expected to grow steadily, supported by high procedure volumes in OB/GYN facilities [8]. - The pelvic surgery segment holds a notable market share, while the urology surgery segment is projected to grow at the fastest CAGR of 8.1% due to rising urological procedures [8]. - The office-based surgery (OBS) segment significantly contributes to market revenue, with the Department of Veterans Affairs (VA) segment expected to experience the fastest growth rate [8]. Future Trends and Recommendations - Healthcare facilities are increasingly investing in advanced gynecological chairs and tables to improve procedural outcomes and patient safety as MIS becomes more prevalent [4]. - The report provides insights into market estimates and forecasts from 2018 to 2030, highlighting growth opportunities and trend analyses [5][9].

Sensus Healthcare (SRTS) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Good day, and welcome to the Sensus Health Care First Quarter twenty twenty five Financial Results Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Turf Patel with Alliance Advisors. Please go ahead. Speaker1 Good afternoon. This is Turf Patel with All ...

May 15, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the “Notes”) under its European Medium Term Note (EMTN) program. The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any Eligible Projects as defined in Philips’ Sustaina ...

Financial Data and Key Metrics Changes - Total reported revenue grew by 4%, while constant currency organic revenue increased by 6% driven by volume and a 20 basis points price increase [6][10] - Gross margin increased by 170 basis points to 44.3%, with positive pricing, favorable mix, and productivity outpacing labor inflation [6][7] - EBIT margin rose by 110 basis points to 24.8% of revenue compared to the previous year [7] - Net income from continuing operations was $270 million, and adjusted earnings per diluted share increased by 14% to $2.74 [7][10] - Free cash flow for fiscal 2025 reached a record $787 million, significantly above guidance due to working capital improvements [8] Business Line Data and Key Metrics Changes - Healthcare constant currency organic revenue grew by 6% for the year, driven by strong recurring revenue streams, while capital equipment revenue declined by 5% [10][11] - Capital equipment orders grew over 12% for the full year, indicating strong underlying demand [11] - AST constant currency organic revenue grew by 9% for the year, with services growing by 7% [12] - Life Sciences saw a 1% increase in constant currency organic revenue, with margins improving to 42.3% [13] Market Data and Key Metrics Changes - The diversified nature of the business allowed the company to deliver results in line with original outlook despite obstacles [10] - The company anticipates revenue growth of 6% to 7% for fiscal 2026 across all segments, with a minor note on AST reflecting high single-digit growth in services [14][15] Company Strategy and Development Direction - The company plans to leverage its strengths to mitigate tariff exposure, with an estimated $30 million impact from tariffs included in the fiscal 2026 outlook [17][18] - The company is well-positioned to deliver both top and bottom line growth in 2026, with no acquisition or divestiture impacts expected [14][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver growth, particularly in recurring revenues and capital equipment orders, despite previous uncertainties in the pharma sector [23][24] - The anticipated tariff impact is expected to be managed strategically, with a focus on mitigating exposure through supply chain adjustments [18][62] Other Important Information - Capital expenditures for fiscal 2025 totaled $370 million, while depreciation and amortization amounted to $476 million [8] - The effective tax rate is planned at approximately 23.5% for fiscal 2026 [18] Q&A Session Summary Question: Comfort in Life Sciences bouncing back to 6% to 7% range - Management noted strong performance in recurring revenues, particularly in consumables, and a rebound in capital equipment orders towards the end of the year [23] Question: Impact of tariffs on EPS - Management discussed various headwinds and tailwinds, including $20 million in restructuring cost savings and lower interest expenses offsetting higher tax rates and tariff impacts [25][26] Question: Cash flow guidance differences - The anticipated $40 million legal settlement for ETO negatively impacts cash flow, along with tariffs and reduced inventory improvements [30] Question: M&A opportunities - Management indicated capacity for M&A from both financial and intellectual perspectives, should the right opportunity arise [32] Question: Onshoring trends - Management suggested that while there are opportunities for onshoring, regulatory complexities may limit rapid shifts in production [36][37] Question: AST growth expectations - Management expressed confidence in accommodating industry growth without capacity constraints [73] Question: Tariff breakdown and mitigation - Management confirmed that the $30 million tariff impact is a net number, with half attributed to China and half to global tariffs, and emphasized ongoing mitigation efforts [58][62]